eCite Digital Repository
Topical application of hyaluronic acid-RGD peptide-coated gelatin/epigallocatechin-3 gallate (EGCG) nanoparticles inhibits corneal neovascularization via inhibition of VEGF production
Citation
Miyagawa, T and Chen, Z-Y and Chang, C-Y and Chen, K-H and Wang, Y-K and Liu, G-S and Tseng, C-L, Topical application of hyaluronic acid-RGD peptide-coated gelatin/epigallocatechin-3 gallate (EGCG) nanoparticles inhibits corneal neovascularization via inhibition of VEGF production, Pharmaceutics, 12, (5) Article E404. ISSN 1999-4923 (2020) [Refereed Article]
 | PDF 2Mb |
Copyright Statement
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) http://creativecommons.org/licenses/by/4.0/
DOI: doi:10.3390/pharmaceutics12050404
Abstract
Neovascularization (NV) of the cornea disrupts vision which leads to blindness. Investigation of antiangiogenic, slow-release and biocompatible approaches for treating corneal NV is of great importance. We designed an eye drop formulation containing gelatin/epigallocatechin-3-gallate (EGCG) nanoparticles (NPs) for targeted therapy in corneal NV. Gelatin-EGCG self-assembled NPs with hyaluronic acid (HA) coating on its surface (named GEH) and hyaluronic acid conjugated with arginine-glycine-aspartic acid (RGD) (GEH-RGD) were synthesized. Human umbilical vein endothelial cells (HUVECs) were used to evaluate the antiangiogenic effect of GEH-RGD NPs in vitro. Moreover, a mouse model of chemical corneal cauterization was employed to evaluate the antiangiogenic effects of GEH-RGD NPs in vivo. GEH-RGD NP treatment significantly reduced endothelial cell tube formation and inhibited metalloproteinase (MMP)-2 and MMP-9 activity in HUVECs in vitro. Topical application of GEH-RGD NPs (once daily for a week) significantly attenuated the formation of pathological vessels in the mouse cornea after chemical cauterization. Reduction in both vascular endothelial growth factor (VEGF) and MMP-9 protein in the GEH-RGD NP-treated cauterized corneas was observed. These results confirm the molecular mechanism of the antiangiogenic effect of GEH-RGD NPs in suppressing pathological corneal NV.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Keywords: | RGD peptide, anti-angiogenesis, corneal neovascularization (NV), epigallocatechin gallate (EGCG), eye drops, gelatin, hyaluronic acid (HA), nanoparticles, drug delivery |
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Medical biotechnology |
| Research Field: | Gene and molecular therapy |
| Objective Division: | Expanding Knowledge |
| Objective Group: | Expanding knowledge |
| Objective Field: | Expanding knowledge in the environmental sciences |
| UTAS Author: | Liu, G-S (Associate Professor Guei-Sheung Liu) |
| ID Code: | 139225 |
| Year Published: | 2020 |
| Web of Science® Times Cited: | 7 |
| Deposited By: | Menzies Institute for Medical Research |
| Deposited On: | 2020-06-02 |
| Last Modified: | 2021-03-24 |
| Downloads: | 3 View Download Statistics |
Repository Staff Only: item control page